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A nutritional approach to prevent, slow, or halt the progression of disease is a promising
strategy that has been widely investigated. Much epidemiologic data suggests that
nutritional intake may inﬂuence the development and progression of Alzheimer’s dementia
(AD). Modiﬁable, environmental causes of AD include potential metabolic derangements
caused by dietary insufﬁciency and or excess that may be corrected by nutritional
supplementation and or dietary modiﬁcation. Many nutritional supplements contain a
myriad of health promoting constituents (anti-oxidants, vitamins, trace minerals, ﬂavonoids,
lipids, . . .etc.) that may have novel mechanisms of action affecting cellular health and
regeneration, the aging process itself, or may speciﬁcally disrupt pathogenic pathways
in the development of AD. Nutritional modiﬁcations have the advantage of being cost
effective, easy to implement, socially acceptable and generally safe and devoid of
signiﬁcant adverse events in most cases. Many nutritional interventions have been studied
and continue to be evaluated in hopes of ﬁnding a successful agent, combination of agents,
or dietary modiﬁcations that can be used for the prevention and or treatment of AD. The
current review focuses on several key nutritional compounds and dietary modiﬁcations that
have been studied in humans, and further discusses the rationale underlying their potential
utility for the prevention and treatment of AD.
Keywords: nutrition, Alzheimer, treatment, clinical trial, prevention

OVERVIEW
Alzheimer’s dementia (AD) is the most commonly recognized
cause of dementia in the aging population (Brookmeyer et al.,
2007). First described by the German psychiatrist and neuropathologist, Alois Alzheimer, in 1906, the eponymous syndrome
is recognized worldwide as a major cause of morbidity and
mortality in the aging population contributing to a major burden on healthcare systems (Brookmeyer et al., 2007). Amyloid
plaque deposition in the brain, the development of neuroﬁbrillary pathology, neuronal loss and dysfunction of neuroanatomic
systems, including those affecting cholinergic transmission, are
among the commonly described ﬁndings in persons with AD
(Jicha and Carr, 2010). In addition to these core pathological
features of AD, much evidence has accumulated that increased
oxidative stress, defects in mitochondrial dysfunction and cellular energy production, and chronic inﬂammatory mechanisms
contribute to the degenerative cascade in this complex disease
(Rao and Balachandran, 2002; Cunnane et al., 2011; RubioPerez and Morillas-Ruiz, 2012). A cure for the condition is not
known and current treatment approaches include maximizing
transmission of acetylcholine and other neurotransmitters while
also using other medications and multidisciplinary strategies
to treat associated comorbidities focused on improving quality of life and alleviating symptom burden (Jicha and Carr,
2010).
A recent NIH scientiﬁc roundtable concluded that there is
no deﬁnitive evidence for beneﬁt of any preventive strategy for
AD, however, this working group also concluded that preventative strategies focused on modifying environmental risk factors
deserves further scientiﬁc exploration and study (Daviglus et al.,
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2011). In response to this consensus statement, there was a broadbased push back by many members of the Alzheimer’s research
community (particularly from the animal model and epidemiological research folks whose data sets were marginalized and
patronized as being of “poor scientiﬁc quality”). Researchers in
the ﬁeld of AD were also underrepresented in the consensus group
leading to further debate as to the validity of the consensus statement. As such it is clear that the ﬁeld is far from consensus on
the debate of whether viable interventions for the prevention of
AD exist. While the search for a cure remains elusive, there is
much hope that preventative strategies, such as dietary modiﬁcation and nutritional supplementation, may reduce the global
burden of AD.
A nutritional approach to prevent, slow, or halt the progression
of disease is a promising strategy that has been widely investigated. Much epidemiologic data suggests that nutritional intake
may inﬂuence the development and progression of AD (GilletteGuyonnet et al., 2013). Modiﬁable, environmental causes of AD
include potential metabolic derangements caused by dietary insufﬁciency (Knopman et al., 2001; Kamphuis and Scheltens, 2010;
Cunnane et al., 2011; Cardoso et al., 2013; Hu et al., 2013; Lopes da
Silva et al., 2014). In addition, many nutritional supplements and
dietary modiﬁcations may directly inﬂuence the pathological contributions of increased oxidative stress, defects in mitochondrial
dysfunction and cellular energy production, chronic inﬂammatory
mechanisms, and even direct pathways to amyloid accumulation
and neuroﬁbrillary degeneration that contribute to the degenerative cascade in AD (Figure 1; Rao and Balachandran, 2002;
Lau et al., 2007; Weih et al., 2007; Pasinetti and Eberstein, 2008;
Kamphuis and Scheltens, 2010; Cunnane et al., 2011; Pocernich
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FIGURE 1 | Diagram of multiple influences of dietary constituents on
cellular pathways and process linked to neurodegeneration in AD.
Antioxidants, trace minerals, ﬂavonoids, metabolic substrates and
modulators, vitamins, and omega-3 fatty acids, among others, have all
been shown to downregulate the many pathological processes linked to
the development of AD, including aging, amyloid deposition, neuroﬁbrillary
degeneration, synapse loss, inﬂammation, metabolic compromise, loss of

et al., 2011; Solfrizzi et al., 2011; Rubio-Perez and Morillas-Ruiz,
2012; Thaipisuttikul and Galvin, 2012; Gillette-Guyonnet et al.,
2013; Hu et al., 2013; Shah, 2013). Nutritional modiﬁcations
have the advantage of being cost effective, easy to implement,
socially acceptable and generally safe and devoid of signiﬁcant
adverse events in most cases. Many nutritional interventions have
been studied and continue to be evaluated in hopes of ﬁnding
a successful compound that can be used for the prevention and
or treatment of AD (Thaipisuttikul and Galvin, 2012; Hu et al.,
2013).
As a discussion of the full complexity of dietary and nutritional
interventions for the prevention of AD could ﬁll a several volume
book series, for the sake of presenting concise determinate clinical
data, the current review focuses on several key nutritional compounds that have been studied in humans, and further discusses
the rationale behind their use. Three fundamentally important
considerations in interpreting the available human data on nutritional supplementation for the prevention of AD include: (1)
Despite our understanding that regulation of metabolic processes
are complex and may require multiple nutritional inﬂuences to
correct aberrant processes leading to AD, traditional experimental
design and study to date has largely focused on the use of single agents. Studies of combination therapies and interventions
are still in their infancy, but may be extremely important for
the identiﬁcation of truly effective nutritional strategies for the
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vascular integrity, and neuronal injury and loss. Note: speciﬁc dietary
factors may have more than one potential mechanism of action on the
pathogenic processes contributing to neurodegeneration in AD. Links
between pathological processes implicated in the development of AD may
not be linear, but rather additive and are shown in a circular fashion
without implication for speciﬁc linkages or temporal associations between
such processes.

prevention of AD; (2) Considerations of dietary excess and the
negative consequences of some dietary constituents (especially
those characterizing the current “Western” diet, may interfere
with the potentially positive effects of speciﬁc nutritional interventions). This has been clearly shown in regards to beneﬁts of
omega-3 fatty acids that are neutralized by high dietary intake
of omega-6 and saturated fats; (3) Our current understanding of
AD includes a prodromal or preclinical phase ranging from 10 to
20 years in which preventative strategies may need to be maintained in order to see their effects. At best, available prevention
data is derived from trials with short intervention periods typically extending to 18 months, with few studies extending to a
3 year period (Table 1). In addition, there is a relative paucity of
“gold-standard,” randomized, double-blind, placebo-controlled,
clinical trials investigating the impact of nutritional supplementation in AD. Despite this caveats, researchers, and clinicians
remain actively engaged in testing the hypothesis that nutritional
approaches may prove benﬁcial for the treatment of AD, while
conceding that continued work in this regard is imperative and
must remain a high priority for funding authorities across the
globe.

ANTIOXIDANTS
Increased oxidative stress has been postulated to be a major
initiating factor or contributor to the neurodegeneration seen in
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CONNECTION, n = 598.

(CONCERT-on donepezil) and
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B12 1 mg qd vs. placebo Aisen et al. (2008).

Folate 5 mg, vitamin B6 25 mg, vitamin

(2013).

vitamin B6 20 mg vs. placebo Douaud et al.

Folic acid 0.8 mg, vitamin B12 0.5 mg and

DHA 2 g qd vs. placebo Quinn et al. (2010).

Mild to moderate AD, n = 409

Mild cognitive impairment, n = 168.

Mild to moderate AD, n = 402.

Mild to moderate AD, n = 204.

1.7 g DHA and 0.6 g eicosapentaenoic acid

vs. placebo Freund-Levi et al. (2006).

(difference score, –1.63 ± 0.76 [–3.1, –0.14, 95%

n = 485.

but not CDR sum of boxes for those lacking an

ADAS-Cog and CDR sum of boxes.

change in ADAS-cog score.

levels (p < 0.001), but had no effect on rate of

None.

(Continued)

homocysteine > 13 mmol/L.

treated vs. placebo group (p < 0.001).
Treatment was effective in reducing homocysteine

The effect was more pronounced for those with

Rate of cerebral atrophy was 3-fold lower in

ApoE ε4 allele.

Reduced rate of decline on ADAS-Cog, MMSE,

MMSE decline rate.

showed a signiﬁcant (p < 0.05) reduction in

Subjects with mild AD, (MMSE > 27 points),

Recognition Memory scores (p < 0.02).

Improved immediate and delayed Verbal

None.

None.

None.

(median 670 days, p < 0.001).

(median 655 days, p = 0.012) or vitamin E

showed delay to endpoints for selegilene

Analyses adjusted for entry MMSE scores

Important secondary outcomes

No effect on primary outcome measures of

MMSE and ADAS-Cog.

No effect on primary outcome measures of

CI], p = 0.03).

Less PAL six pattern errors with DHA vs. placebo

Normal cognition with memory complaints,

(2010).

No effect on ADAS-Cog outcome measures.

900 mg qd of DHA Yurko-Mauro et al.

CONNECTION Bharadwaj et al. (2013).

Mild to moderate AD, CONCERT, n = 1050;

Latrepirdine 5 or 20 mg qd vs. placebo

by 19% from baseline to week 16 in the E/C/ALA
group but were unchanged in the other groups.

oxidative stress biomarker, decreased on average

Cerebrospinal ﬂuid F2-isoprostane levels, an

rate of decline. No effect of memantine.

group than placebo representing a 19% slowing in

ADCS-ADL scores decline 3.15 less in vitamin E

900 mg α-lipoic acid; 1200 mg coenzyme Q

Mild to moderate AD, n = 78.

Mild to moderate AD, n = 613.

qd Galasko et al. (2012).

800 IU vitamin E and 500 mg vitamin C and

qd Dysken et al. (2014).

Vitamin E 2000 IU qd; memantine 20 mg

disease, institutionalization, or death.

No difference between groups for progression of

Moderate AD, n = 341.

Selegiline 10 mg qd; vitamin E 2000 IU qd

Sano et al. (1997).

Main findings

Subjects

Study intervention

Table 1 | Prospective, randomized, placebo-controlled clinical trials of nutritional interventions in the prevention and treatment of AD.
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error) SE = 0.57, p = 0.513).
No signiﬁcant difference in change in ADAS-cog

Shah et al. (2013)].

Huperzine A (200 mg BID [n = 70]

www.frontiersin.org

neuropsychological domains of memory, attention,
visual-spatial construction, language, and executive
functions did not differ between groups.

of dementia was 1.12 (95% conﬁdence interval
[CI], 0.94−1.33; p = 0.21) and for AD, 1.16 (95%
CI, 0.97–1.39; p = 0.11).

(n = 482).

placebo DeKosky et al. (2008), Snitz

mg, milligrams; IU, international units; qd, every day; AD, Alzheimer’s disease; MMSE, Folstein Mini Mental State Examination score; ADAS-Cog, Alzheimer Disease Assessment Scale-cognitive subtests; POC,
proof-of-concept; DHA, docosahexaenoic acid; MCT, medium chain triglycerides; BID, twice daily; MCI, mild cognitive impairment; 3MSE, Modiﬁed Mini-Mental State Examination.

et al. (2009).

Rates of change over time in 3MSE, ADAS-Cog, and in

Hazard ratio for G. biloba vs. placebo for incidence

Normal adults (n = 2587) and MCI

Ginkgo Biloba 120 mg BID vs.

LOCF ANCOVA).

trend 1.92 ± 5.30 point improvement (p = 0.07 for the

vs. –0.34 ± 5.17, p = 0.98).

Raﬁi et al. (2011).

Huperzine A 400 mg BID treatment effects on
ADAS-Cog change demonstrated a non-signiﬁcant

scores for Huperazine 200 mg BID (–0.32 ± 15.37

or 400 mg BID [n = 70]) vs. placebo

Mild to moderate AD, n = 210.

study groups [difference = 0.37 points, (standard

DHA, uridine, choline [Souvenaid® ;

Combination supplement with

None.

but not the control group.

baseline ADAS-cog (F [1,250] = 1.25, p = 0.265).
No signiﬁcant difference in ADAS-cog between

group (correlation coefﬁcient = –0.260; p = 0.019),

baseline ADAS-cog, but not in patients with “low”
Mild to moderate AD, n = 527.

with ADAS-cog improvement in the active product

p = 0.046) was shown in patients with “high”

Kamphuis et al. (2011)].

Combination supplement with

DHA, uridine, choline [Souvenaid® ;

Baseline in ADAS-Cog scores at Day 45 (p = 0.0005).

p = 0.0235 in ITT favoring treatment.

Overall, intake adherence was signiﬁcantly correlated

Mild AD, MMSE 20–26, n = 225

ε4(–) participants (n = 55) administered AC-1202 had a
signiﬁcant 4.77 point difference in mean change from

ADAS-Cog score on Day 45: 1.9 point difference,

A signiﬁcant treatment effect (F [1,319] = 4.0,

vs. placebo Henderson et al. (2009).

Oral ketogenic compound, AC-1202

Mild to moderate AD, n = 152

with MCT administration (r = 0.50, p = 0.02).

et al. (2004).

levels were higher showed improved paragraph recall

triglycerides as a placebo Reger

in ADAS-cog scores following MCT treatment

In the ε4-group, there was a signiﬁcant improvement

MCTs, or emulsiﬁed long chain

composite groups.

(n = 5).

isocaloric conditions (690 calories)

(F [1,7] = 6.36, p = 0.04). Subjects whose β-OHB

No effect on primary outcome measures for the

AD (n = 15) or mild cognitive impairment

Subjects received one of two

Important secondary outcomes

in a randomized order: emulsiﬁed

Main findings

Subjects

Study intervention

Table 1 | Continued
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AD (Filipcik et al., 2006). There is much debate as to the type of
antioxidant that may afford the most protection. Some antioxidants preferentially target cytosolic oxidative stress pathways
whereas others preferentially serve as mitochondrial cofactors that
may reduce intrinsic oxidative stress mechanisms (Filipcik et al.,
2006). Antioxidants function in many ways, reducing oxidized
membrane lipids, preventing carbonylation of proteins, limiting
nucleic acid damage, and inﬂuencing stress kinase pathways. Such
pleiotropic mechanisms of action inherent in the properties of
any given antioxidant preclude precise determination of speciﬁc
cellular injury or pathway modulation that might be responsible
for the beneﬁcial effects of antioxidants in in vitro and in animal models of AD. Irrespective of the many potential sites of
action and inﬂuences on complex cellular pathways inﬂuenced
by antioxidants, the hypothesis that antioxidant therapy may prevent or slow the development of AD has given rise to many human
clinical studies that have provided a much data on the potential risks and beneﬁts of antioxidant therapy in the treatment
of AD.
Laboratory research has demonstrated that cytosolic antioxidants, such as vitamin E (α-tocopherol), can prevent AD-like
changes in the brains of genetic AD mouse models (Nishida
et al., 2006). Other antioxidants such as selegiline, a monoamine
oxidaseβ inhibitor, that also inhibits oxidative deamination, have
also shown neuroprotective properties in animal models of degenerative disease although deﬁnitive human data is lacking in this
regard (Tatton, 1993). The Alzheimer’s Disease Cooperative Study
Group (ADCS) evaluated these ﬁndings in a pivotal clinical trial
that examined whether treatment with selegiline or α-tocopherol
slowed the progression of disease in patients with moderately
severe impairment from AD. Treatment with selegiline (15 mg
twice daily) and α-tocopherol (1000 IU twice daily) increased
median survival by 215 and 230 days over the placebo, respectively (Sano et al., 1997). These ﬁndings led to widespread use
of a daily dose of 2000 IU α-tocopherol to slow progression in
AD. Widespread use of α-tocopherol supplementation at this dose
permeated the ﬁeld until a meta-analysis suggesting an absolute increase in all-cause mortality of 39/10,000 subjects in the
pooled data (p = 0.035; absolute risk ratio = 0.0039; number needed to harm = 256) from doses higher than 400 IU
per day was published in Miller et al. (2005). The debate on
whether vitamin E is protective or deleterious has raged on,
with many cautious of the potential adverse effects of such
high dose supplementation until 2013 when the ADCS study
results were replicated in a large scale “gold-standard” clinical trial, again supporting the use of α-tocopherol at doses
of 2,000 IU per day for the treatment of AD (Dysken et al.,
2014). Vitamin E should be taken in conjunction with vitamin
C as a recharging antioxidant that maximizes the dose of vitamin E. Wheat germ, sunﬂower, and safﬂower oils, leafy green
vegetables, and asparagus are among the best food sources of
vitamin E.
In addition to its effects in combination with vitamin E, vitamin C (ascorbic acid) has been widely studied for the prevention
and treatment of AD (Bowman, 2012). Vitamin C is an essential vitamin that cannot be produced by humans from glucose
or other substrates. Fortunately dietary sources of vitamin C are
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common and include citrus fruits, berries, and many vegetables that are a common part of most human diets worldwide.
Several epidemiologic and cohort studies have investigated the
association of vitamin C dietary intake and supplementation with
AD and cognitive function in elderly humans. The data from
well-characterized cohorts and epidemiologic populations include
33,252 subjects combined and only 3 of these 8 studies have suggested beneﬁt of vitamin C intake (reviewed in Bowman, 2012).
Further work examining plasma levels of vitamin C in seven studies (n = 1951 combined) showed a signiﬁcant inverse association
of vitamin C with AD and cognitive impairment that was universal across all cohorts studied. Four small studies have looked
directly at CSF levels of vitamin C in relation to cognitive performance and AD (n = 122 combined), with 3 of the 4 studies
showing a positive relationship. These data suggest that dietary
intake may be less important than the biological levels attained
through dietary intake of vitamin C (reviewed in Bowman, 2012).
Unfortunately “gold-standard,” large, multi-center, prospective,
randomized, placebo-controlled trials have not been conducted
to date. Such studies are needed to determine if prospective supplementation with vitamin C can modify the pathological process
responsible for AD. Nonetheless, risks associated with vitamin C
supplementation have not been seen in any human studies to date,
and the cumulative available data from cross sectional, retrospective cohort, and epidemiological studies suggest that a potential
beneﬁt may exist.
Other studies have shown some beneﬁt from mitochondrial
cofactors that may function to reduce oxidative stress such as
coenzyme Q10 (CoQ10) in reducing amyloid plaque deposition
in mice models of AD (Yang et al., 2010). CoQ10 plays a role in
the ubiquitin–proteasome complex pathway in the mitochondria
that deals with aerobic respiration and cellular breakdown product disposal; a process that is thought to contribute to amyloid
plaque formation and accumulation. CoQ10 is easily available and
has not associated with any signiﬁcant adverse events in numerous studies across disparate medical conditions (Hidaka et al.,
2008). CSF penetration of CoQ10 is limited however, with maximal availability in the heart, liver, and kidneys (Bhagavan and
Chopra, 2006). Nevertheless, it remained a promising agent in the
array of antioxidants being used in AD until a recently published
head-to-head comparison of cytosolic (α-tocopherol) and mitochondrial (CoQ10) antioxidants was performed in patients with
mild to moderate AD (Galasko et al., 2012). The results of this
short 4-month study demonstrated beneﬁt of cytosolic antioxidants in reducing isoprostane levels in cerebrospinal ﬂuid, whereas
CoQ10 showed no biological beneﬁt in the central nervous system
(CNS; Galasko et al., 2012).
Other molecules of recent interest include latreperdine (Dimebon) which was a repurposed antihistamine from Russia that led
the ﬁeld in interest and speculation as a new potential agent for
the treatment of AD in the earlier part of this decade (Doody,
2009). The mechanism of action for latreperdine was an enigma
until a wealth of data was produced suggesting its mechanism of
action was in blocking the mitochondrial membrane pore complex and reducing or protecting mitochondria from the adverse
effects of oxidative stress (Bharadwaj et al., 2013). Unfortunately
the intrigue and excitement was short-lived as latreperdine soon
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proved to be ineffective in modifying AD progression in several
global Phase-III studies (Bharadwaj et al., 2013). The question as
to whether other mitochondrial antioxidants may have utility in
the prevention and treatment of AD remains unanswered.
Organic selenium is another antioxidant that is being investigated currently in human clinical studies (Zhang et al., 2010).
It is available in several forms, with varied biological actions
and efﬁcacy in laboratory paradigms. While inorganic selenium
is poorly absorbed, selenomethionine, and yeast-selenium are
much more bioavailable after supplementation (Zhang et al.,
2010). Animal studies suggest profound effects on brain health
and the ability to signiﬁcantly reduce AD pathology in genetic
mouse models (Xiong et al., 2007). These ﬁndings have led
to the use of antioxidant therapy including vitamins c, e,
and selenium in the largest prevention trial of AD ever conducted, the PreADViSe trial, Prevention of AD by Vitamin E
and Selenium (Kryscio et al., 2013). This trial remains ongoing and currently no data exists for beneﬁts of selenium
supplementation in the prevention or treatment of AD in
humans.
Lipoic acid, β-carotene, and other bioﬂavonoids are just a
few of the other antioxidants that have been evaluated for their
actions on mitochondrial enzymes like superoxide dismutase and
α-ketoglutarate dehydrogenase. Results from clinical trials with
these agents have not been sufﬁcient or warranted changes in recommendations for practice. Clearly further work including early
stage prevention trials are needed before the utility or lack thereof
of antioxidant therapy in the prevention and treatment of AD can
be established.

OMEGA-3 FATTY ACIDS
Fatty acids are found in all the body cells as part of the cell membranes and play a major role in cell membrane stability, ﬂuidity,
and synaptic connectivity (Jicha and Markesbery, 2010). Fatty
acid oxidation by free radicals results in cell membrane damage and has been postulated to contribute to the pathogenesis
of AD, although other roles of unsaturated fatty acids such as
lipid raft formation and maintenance of synaptic integrity and
function have taken on a primary role in the hypothesis that
supplementation with such agents may prevent or slow AD progression (Jicha and Markesbery, 2010). Docosahexaenoic acid
(DHA) and eicosapentaenoic acid (EPA) are the major omega3 fatty acids that have been studied in human clinical trials to date
(Jicha and Markesbery, 2010). DHA is the most abundant omega3 fatty acid in the brain. Polyunsaturated fatty acids (PUFAs)
like DHA and EPA allow for lipid raft formation across their
unsaturated moieties to absorb the oxidative stress of free radicals and increase cell membrane ﬂuidity necessary for lipid raft
creation and formation of effective synaptic contacts (Jicha and
Markesbery, 2010). It is currently unclear what the best source
of and or combination of speciﬁc omega-3 fatty acids might
be for the prevention or treatment of AD and so many different sources and formulations have been tested in human clinical
trials.
Fish oil, rich in omega-3 fatty acids, when consumed regularly
has been found to lower the incidence of AD in epidemiologic
studies (Jicha and Markesbery, 2010). Several of these studies have
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found confounders such as apolipoprotein E (ApoE) allele status and omega-6 intake that have limited the reliability of studies
across cohorts (Jicha and Markesbery, 2010). Several studies have
demonstrated a lack of association of omega-3 supplementation
on a background of a diet high in omega-6 fatty acids, which
act similarly to saturated fatty acids decreasing membrane ﬂuidity in opposition to the effects of omega-3 fatty acids (Jicha and
Markesbery, 2010). These data suggest that nutritional beneﬁt may
be overcome or canceled in the presence of negative dietary contributions. It is intriguing that the dramatic increase in the prevalence
of AD over the last century not only parallels the increase in average lifespan, but also an increase from 2 to more than 20 of the
ratio of omega-6 to omega-3 PUFAs in the average Western diet
(Yehuda et al., 2005). ApoE status may be a further modulator of
omega-3 beneﬁt that is discussed further below.
Nonetheless, the epidemiologic and scientiﬁc data have led to
several large scale clinical trials of omega-3 fatty acids in AD and in
normal aging. The MIDAS study found that daily dietary supplementation with 900 mg of DHA produced 7 year age improvement
in cognition over just 24 weeks as compared to placebo in elderly
patients with cognitive decline (Yurko-Mauro et al., 2010). One
large scale trial of ﬁsh oil supplementation in Europe showed
potential beneﬁt for only those subjects with Folstein Mini-Mental
Status scores greater than or equal to 27 (Freund-Levi et al.,
2006). Another large scale, multicenter, double-blind, randomized, placebo-controlled trial of high dose DHA supplementation
failed to meet primary endpoints for success, but in preplanned
secondary analysis a beneﬁt was seen for subjects with mild to
moderate AD who were negative for the ApoE ε4 allele (Quinn
et al., 2010). The effect of ApoE ε4 responsible for negating the
beneﬁcial effects of omega-3 fatty acids is poorly understood, but
has been seen in both epidemiologic studies and prospective clinical trials. Carriers of this allele appear to show no beneﬁts of DHA
supplementation. This could be due to differences in lipid transport mechanisms or to direct effects on β-amyloid production
and clearance. The potential for prevention of AD with omega-3
fatty acid supplementation in non-carriers of the ApoE ε4 allele
deserves further study as this population represents nearly 60% of
those affected by AD (Jicha and Carr, 2010). Prevention or slowing of the disease process in even this subgroup of sporadic AD
cases would have a major impact on the prevalence and health
care cost burden associated with AD worldwide. While further
work is clearly needed, our current data demonstrates that DHA
is well tolerated and has not shown any signiﬁcant adverse events
in these studies and further large scale trials in both normal aging
and AD are currently underway.
In addition to potential direct effects on neurodegeneration in
AD, the beneﬁts of omega-3 fatty acids for reducing cerebrovascular disease are widely recognized and may provide additional
beneﬁt in those suffering from AD, in whom cerebrovascular disease may be the most common comorbidity (Jicha and Carr,
2010). Omega-3 fatty acids reduce circulating cholesterol levels,
inhibit systemic inﬂammation in the circulatory system and vasculature, and inhibit platelet aggregation (Jicha and Markesbery,
2010). The potency of such effects in limiting cognitive decline in
AD patients with comorbid cerebrovascular disease may be fundamental for the beneﬁt of omega-3 fatty acids seen in human
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B VITAMINS AND FOLATE
Several studies have shown that elevated serum homocysteine levels and lower vitamin B12 levels are associated with an increased
risk of AD (Seshadri et al., 2002; Morris, 2003, 2012; Malaguarnera
et al., 2004). Serum folate levels have not shown the same association with AD (Morris, 2002). However, the association of folate
with homocysteine metabolism is well known.
Most of the B complex vitamins have been shown to be directly
or indirectly associated with neuronal health due to their involvement with neuronal metabolic pathways. Essential functions of
the B vitamins include their role in energy metabolism through
their action as methyl donors. Deﬁciency of such vitamins has
been directly linked to the development of speciﬁc neurological
disorders, such as subacute combined degeneration (B12 deﬁciency), pellagra (vitamin B6 deﬁciency), Wernicke’s/Korsakoff ’s
(B1 deﬁciency). Current clinical recommendations include routine laboratory analysis of such vitamin levels, and repletion if
found to be deﬁcient in the setting of cognitive impairment or
decline (Knopman et al., 2001). Only limited evidence is available on the effect of supplementation with these vitamins in
replete states, although one study found a beneﬁcial effect of
B complex vitamin supplementation in slowing the onset or
progression of AD in cerebral gray matter although more data
analysis is needed to elucidate the exact beneﬁts of these vitamins
(Douaud et al., 2013).
Cerefolin NAC is a product containing methylcobalamin,
methylfolate and acetylcysteine and is approved for treating vitamin deﬁciencies associated with memory loss (Thaipisuttikul and
Galvin, 2012). Evidence for its use is limited and research is ongoing, despite wide media and consumer appeal. Other clinical trials
investigating folic acid and vitamin B supplementation have failed
to show convincing results in neurologic improvement despite
universal correction of deﬁciencies and downstream homocysteine levels, and as such the role of high dose B vitamin and folic
acid supplementation in the prevention of AD has yet to be established (Aisen et al., 2008; Dangour et al., 2010; Daviglus et al., 2010;
Morris, 2012).

(Reger et al., 2004). Higher plasma levels of ketones like βhydroxybutyrate were directly correlated with higher performance
in memory scores during this study (Reger et al., 2004). Interestingly enough, the beneﬁts of higher ketone levels were only seen in
ApoE4 negative patients during this study, similar to the selective
beneﬁts of omega-3 fatty acid supplementation seen in ApoE ε4
non-carriers described above.
Widespread media attention has recently been paid to the
notion that coconut oil may be a treatment for AD (DeDea, 2012).
This was prompted by the posting of a short video that went
“viral” on You-tube showing dramatic improvements in a patient
with AD with such dietary modiﬁcation. The video included commentary from his wife, a pediatrician, who was familiar with the
ketone diet used for intractable seizures in this population. The
video and case itself has not been published scientiﬁcally and it
is uncertain if it actually represents true events or is ﬁctitious in
nature. In addition, the claim of efﬁcacy for coconut oil use in
AD has not been substantiated in any case report in the medical and scientiﬁc literature. The postulated mechanism for the
effect was the content of caprylic acid, a MCT, that restored brain
function as portrayed in this video (DeDea, 2012). Deﬁnitive scientiﬁc and or clinical evidence for an effect of coconut oil for the
prevention or treatment of AD remains to be seen, as no clinical trial data is as of yet available to substantiate or refute these
claims.
A nutritional supplement, labeled as a medical food (Axona® ),
containing octanoic acid or caprylic acid has been studied for
its potential beneﬁts in AD (Henderson et al., 2009). Supplementation with Axona® in AD patients has been shown to produce
improvement in cognition when measured at 45 and 90 days
of supplementation (Henderson et al., 2009). Again, the beneﬁts are seen only in ApoE4 ε4 allele negative patients and are
short-lived (Henderson et al., 2009). While the beneﬁt remains
uncertain, the risks appear minimal, and this strategy is taking
root in the armament of treatments many clinicians offer their
patients with AD. The most common reasons for discontinuation of Axona® were adverse events like diarrhea, ﬂatulence, and
dyspepsia (Henderson et al., 2009). Caution should be exercised
before prescribing Axona® or other supplements containing MCTs
in patients with diabetes, gastrointestinal inﬂammation, metabolic
syndrome, and renal disturbances as these may amplify the risk of
adverse events.

MEDIUM CHAIN TRIGLYCERIDES (AXONA AND COCONUT
OIL)
While glucose acts as the primary metabolic substrate in the brain,
ketone bodies derived from medium chain triglycerides (MCTs)
can serve as an alternative energy source in the brain. Much
research has suggested that a localized, brain-speciﬁc, insulin resistance develops in AD leading to neuronal dysfunction and death
(Craft et al., 2013; de la Monte and Tong, 2014). These data have
prompted some to propose ketogenic supplements as a possible
strategy for the treatment of AD (Kashiwaya et al., 2013; Zhang
et al., 2013; Zilberter et al., 2013).
Patients with memory impairment showed signiﬁcant
improvement in memory after receiving oral supplementation
with MCTs that produced higher ketone levels in the blood

COMBINATION MEDICAL FOODS (Souvenaid® )
Nutritional approaches to inﬂuencing the course and progression
of AD are among the newer strategies being implemented by scientists. Specially designed medical foods in various combinations are
being used to target the underlying process in AD. The rationale
behind this approach is that AD results from or causes biochemical
alterations in metabolic pathways that are complex and dependent
on multiple nutritional compounds and co-factors. Targeting such
complex pathways may require combination therapy for maximal
success and the use of single agent supplementation may simply
be ineffective outside of the rare patient that may have a speciﬁc
nutritional deﬁciency. Current innovative approaches include supplying such nutrient combinations in an artiﬁcial form to enhance
synaptic health and neuronal stability.

studies. Further studies aimed at distinguishing direct effects on
AD pathogenesis and those associated with the abrogation of
cerebrovascular disease are needed to resolve this fundamentally
important issue.
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Souvenaid® is a medical food designed to contain just such a
nutrient combination. Also known as Fortasyn Connect® , this
medical food is designed to promote synaptic formation and
function (Kamphuis et al., 2011; Shah et al., 2013). The product
includes precursors (uridine monophosphate; choline; phospholipids; EPA; DHA) and cofactors (vitamins E, C, B12, and B6; folic
acid; selenium) necessary for the formation of synapses, integrity
of neuronal membranes, resistance to oxidative stress, and optimal
metabolic activity in the brain (Kamphuis et al., 2011; Shah et al.,
2013).
The existing data have shown mixed results for this approach.
One study did not ﬁnd signiﬁcant beneﬁts from using Souvenaid®
while another showed that patients in the early stage of AD with
higher baseline function showed cognitive improvement with
higher doses of Souvenaid® (Kamphuis et al., 2011; Shah et al.,
2013). Additional trials with reﬁned patient populations and optimized outcome measures may be needed to establish the beneﬁt
of this approach.

DIETARY INFLUENCES ON AD AND DIETARY MODULATION
FOR THE PREVENTION OF AD
While the available scientiﬁc research and clinical trial data on
nutritional interventions in AD have focused on single agents or
simple combination therapies, a more holistic approach involves a
broader examination of complex dietary inﬂuences that may not
be easily adapted to scientiﬁc study and rigorous clinical examination. Evolutionary Discordance Theory suggests that chronic
disease conditions are caused by evolutionary changes in diet
(Cordain et al., 2005). This theory has some basis in observational data and on the consideration of the primal hominid diet
in the hunter-gatherer Paleolithic era as essential consisting of
minimally processed, wild plant and animal foods (Cordain et al.,
2005). The rise of many chronic health conditions have paralleled the development of our agrarian culture, now consuming a
diet rich in highly processed carbohydrates, reﬁned sugars, alcohols, saturated vegetable oils, dairy products, and fatty domestic
meats (Cordain et al., 2005). In light of this theory it is intriguing
that an increased risk for AD has been linked to all these evolutionary dietary changes, which include an increase in glycemic
index and fatty acid composition of the diet, alterations in macroand micronutrient composition, increase in sodium intake, and
decrease in ﬁber content (Rao and Balachandran, 2002; Lau et al.,
2007; Weih et al., 2007; Pasinetti and Eberstein, 2008; Kamphuis
and Scheltens, 2010; Cunnane et al., 2011; Pocernich et al., 2011;
Solfrizzi et al., 2011; Rubio-Perez and Morillas-Ruiz, 2012; Thaipisuttikul and Galvin, 2012; Gillette-Guyonnet et al., 2013; Hu
et al., 2013; Shah, 2013). Such dietary changes have been linked
to the rise in prevalence of metabolic syndrome that has been
further associated with the rise in AD prevalence in western
society.
Metabolic syndrome is deﬁned by the presence of at least three
of the following: abdominal or central obesity (waist circumference >102 cm for men and >88 cm for women); elevated
plasma triglycerides (TGs; ≥150 mg/dl); low high-density lipoprotein (HDL) cholesterol (<40 mg/dl for men and <50 mg/dl for
women); high BP (≥130/≥85 mm Hg) or normotensive on hypertensive treatment; high fasting plasma glucose (≥110 mg/dl) or
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euglycemic on antidiabetic treatment (Grundy et al., 2005). This
combination of central obesity, hyperlipidemia, hypertension, and
insulin resistance or type II diabetes has been strongly linked with
increased risk for development of AD (Frisardi et al., 2010). The
metabolic syndrome has been clearly associated with increased
risk for cerebrovascular disease which is a substantial comorbidity and confounding contributor to the development of AD in
community based cohorts, but also may directly increase systemic
and CNS inﬂammation processes linked to AD through induction of adipokines that modulate these processes (Panza et al.,
2010; Solfrizzi et al., 2010). While the components of metabolic
syndrome are highly dependent on diet, contributions of other
lifestyle factors leading to the metabolic syndrome, such as reduced
exercise, should not be minimized (Grundy et al., 2005). While
several studies examining pharmacologic manipulation of hypertension and hyperlipidemia have demonstrated cognitive beneﬁt
in the aging population, no interventional studies focused on
nutritional correction of the complete metabolic syndrome in
the prevention of AD exist in the literature today (Tzourio et al.,
2003; Masse et al., 2005; Rockwood, 2006). Despite such positive
results, large scale, multi-center, randomized, placebo-controlled
human clinical trials of statins to reduce cognitive decline associated with AD have failed to date, leaving many to question
the potential impact of modulating a single or isolated component of the metabolic syndrome in light of the complex,
multifaceted, pathways involved in the development of AD (Sano
et al., 2011).
Caloric restriction may counter the negative consequences of
metabolic syndrome, has been investigated widely, and has shown
cross species beneﬁts in slowing aging process and extending
expected lifespan (Gillette-Guyonnet and Vellas, 2008). The brain
beneﬁts of caloric restriction may be attributable to induction of
neurogenesis and enhancement of synaptic plasticity, potentially
protecting the brain from age-related senescence and allowing
increased recovery and compensation following neuronal injury
or in the face of degenerative processes such as AD (GilletteGuyonnet and Vellas, 2008). While animal data is robust, little
human data has been acquired to date on the role of caloric
restriction in preventing AD.
People living in the Mediterranean region, especially Naples
and the surrounding parts of Italy, have been found to have the
highest life expectancies in the world and have also been found
to have lower incidence of AD. This observation has convinced
many authorities to attribute this to their dietary habits. The
Mediterranean diet is extremely well known and popularly recommended as a preventive measure for AD and cognitive impairment
(Feart et al., 2010; Soﬁ et al., 2010). Although there is no ﬁxed
recipe for this diet, generally speaking, a diet with generous servings of fruits, vegetables, whole grains, beans, nuts, seeds with
low to moderate amounts of ﬁsh, poultry, dairy products, and
low amounts of red meat is seen in most variations of this diet.
Such diets have been shown to modulate inﬂammatory, oxidative stress-induced, regenerative, and cellular health processes that
may play critical roles in modulating risk for AD. Olive oil forms
an important component of this diet and is rich in monounsaturated fatty acids (MUFAs) and oleocanthal, the latter being shown
to have inhibitory properties on ﬁbrillization of tau protein, thus
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conferring it with potentially protective properties in AD (Monti
et al., 2011). Epidemiologic studies have shown that higher adherence to a Mediterranean-style diet results in reduced mortality in
patients with AD in a dose responsive manner with greater compliance and dosage being associated with greater beneﬁts (Scarmeas
et al., 2007). Research has also shown that greater consumption of
Mediterranean diet with higher compliance was associated with a
lower risk of AD (primary prevention) and slower progression of
symptoms (secondary prevention) of mild cognitive decline into
AD (Scarmeas et al., 2006; Solfrizzi et al., 2011).
The beneﬁts of the Mediterranean diet have been attributed
to the presence of MUFA and PUFA in addition to the right
mix of micro and macronutrients that promotes neuronal health
and minimizes AD risk. “Gold-standard” clinical trial is not
yet available for such dietary interventions given the complexity of practical implementation. Additional considerations not
answered by the epidemiologic data include possible effects of
genetic background (ApoE status as seen for other nutritional
approaches), duration of dietary modiﬁcation needed before beneﬁt may be evident, and confounding lifestyle factors that may
inﬂuence response to such dietary approaches or inﬂuence the
outcome disease state and processes. Despite these caveats, the
adage “You are what you eat” may hold true and the health
beneﬁts of a Mediterranean-style diet are well accepted across
multiple disciplines of medicine with no adverse potential or
limitations for the general population. Only limited studies of
other diets have been published to date with no clear evidence
emerging.
Unfortunately, as clinical interventions of total dietary intake
and composition are limited by the complexity of the human diet,
the best available data for dietary inﬂuences in the prevention
of AD come from retrospective cohort and epidemiologic studies rather than from prospective clinical trials. This is in large
due to the many confounds inherent in total dietary regulation
required to establish causality and the potential beneﬁt of prospective dietary modiﬁcation. With these caveats in mind, it is still
worthwhile to consider the emerging evidence that modiﬁcation
of dietary patterns, including caloric restriction, and avoiding the
current “Western” diet, may prove to be effective strategies for the
prevention of AD.

OTHER NUTRITIONAL SUPPLEMENTS EVALUATED IN
HUMAN CLINICAL TRIALS
Apart from the nutritional substances mentioned above, a myriad
of other natural supplements have potential to modify the development and progression of AD, although deﬁnitive evidence for
efﬁcacy is still lacking. Many of these agents are commonly used
in traditional medicine culture in India, China, and other areas
of Eastern Asia and have generated a great deal of interest in their
potential therapeutic beneﬁt for AD in Western society.
Huperzine A is a traditional Chinese herb, with pharmacological actions as an acetylcholinesterase inhibitor (AChEI) among
other properties that has been evaluated in several small clinical
trials that have suggested potential beneﬁt in AD patients (Yang
et al., 2013). In the laboratory, huperzine A has been shown to
reduce amyloid plaque formation and abrogate cell death by altering neuronal iron content in animals models of AD (Huang et al.,
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2014). A recent multicenter clinical trial of Huperzine A failed to
meet primary endpoints for success suggesting its potential beneﬁts may be limited in human disease, however, the study suffered
from several limitations, including the concomitant use of pharmacological AChEI that have diluted the effects of the herb that
would otherwise have been seen in drug-naïve populations (Raﬁi
et al., 2011).
Gingko biloba, another Chinese herb, has also been studied for
potential beneﬁt in AD. It contains ginkgolide B, a platelet activating factor (PAF) antagonist, and has been used in stroke trials
due to this property. A large scale primary and secondary prevention study analyzed the efﬁcacy of gingko biloba in preventing the
development of or slowing progression of mild cognitive impairment into AD and found no beneﬁts (DeKosky et al., 2008; Snitz
et al., 2009). Despite this failure, it continues to be a popular treatment for a variety of medical conditions and may yet hold promise
for the treatment of vascular cognitive impairment and dementia
related to other non-AD causes.
Resveratrol is a polycyclic aromatic compound found in skins
of grapes, raspberries, mulberries in varying concentrations that
has been found to have powerful antioxidant properties (natural
plant polyphenol; Pervaiz and Holme, 2009). Laboratory studies
have shown multiple mechanisms of action including function
as a powerful antioxidant, decreased amyloid plaque deposition
in animal models of AD, and inhibition of intracellular inﬂammatory pathways that predispose to cellular breakdown and cell
death (Anekonda, 2006; Pervaiz and Holme, 2009). Perhaps the
most interesting data of all links resveratrol to sirtuin pathways
that are key mediators of cellular aging processes, suggesting it
may promote longevity (Anekonda and Reddy, 2006). Animal
studies have demonstrated that resveratrol improves the health
and survival of mice fed a high calorie diet (Baur et al., 2006).
Thus, resveratrol may not only inﬂuence AD pathways, but may
also enhance metabolic activity, thereby reducing risks for obesity
and cerebrovascular disease that can contribute to the development of dementia, in addition to reductions in cellular aging
processes (Baur et al., 2006). As age remains the major risk factor for AD, resveratrol is being tested currently in a multicenter
clinical trial in mild to moderate AD patients in addition to a
widespread range of other age-related diseases1 . Available safety
data suggests that supplementation with resveratrol is relatively
benign although no current recommendations as to its usefulness
van be made without more human data including the results of
the ongoing trial.
Turmeric is a spice used commonly in eastern cuisines and
has been associated with antioxidant properties that have spiked
interest in its role on treating or preventing cancer, aging and AD.
Curcumin, the active ingredient of turmeric, has been shown to
have antioxidant scavenging properties and increase glial ﬁbrillary
acid protein expression in hippocampi of mice and increase spatial
memory (Wang et al., 2013; Fang et al., 2014). Curcumin exhibits
powerful anti-inﬂammatory effects through its downregulation of
proinﬂammatory transcription factors including nuclear factorkappa B, signal transducer and activators of transcription-3, and
Wnt/beta-catenin (Aggarwal, 2010). Curcumin has additionally
1 http://www.clinicaltrials.gov/ct2/show/NCT01504854
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been shown to directly reduce amyloid plaque formation and associated inﬂammation in the brains of AD Mouse models (Wang
et al., 2013). Two studies have published or presented the data from
these trials to date, both showing excellent safety proﬁles of curcumin, but neither showing beneﬁt in regards to clinical efﬁcacy
or inﬂuences on traditional AD biomarkers (Baum et al., 2008;
Ringman et al., 2008). Several other human trials are currently
underway2 , however, deﬁnitive data is not yet available on the
inﬂuence of this nutritional agent in the prevention or treatment
of AD in humans.

SUMMARY
A nutritional approach to preventing AD appears to be an innovative and safe approach that may be extremely cost effective,
allow ease of administration, and importantly, serve as a socially
acceptable intervention or adjunctive approach in the prevention and treatment of AD. Despite years of scientiﬁc, medical,
and clinical advances in this area, much remains to be discovered and proven in terms of speciﬁc nutritional interventions
for the prevention of AD. Promising agents such as vitamins,
energy substrates, ﬂavonoids, lipids, and modiﬁed diets functioning as anti-oxidants, metabolic-enhancers, immune-modulators,
and direct disease-modifying agents await further investigation. To
date no deﬁnitive evidence for disease modiﬁcation outside of animal and in vitro experiments exist, and yet human clinical data is
beginning to suggest that such interventions deserve further study
(Table 1).
Yet it is possible, despite the wealth of retrospective and
prospective human data available that nutritional interventions
for the prevention of AD may be effective, it is equally possible
that they may serve to only supplement direct disease-modifying
treatment, and in themselves are ineffective at modulating the AD
disease state. Human evolutionary dietary data does not take into
account the extended lifespan see in modern day humans, and so
evidence supporting evolutionary reversion of diet may be misleading. Evidence from studies of omega-3 fatty acids like DHA
and energy substrates like Axona® suggest that disease modulation
of nutritional intervention may be genetically modulated (Reger
et al., 2004; Quinn et al., 2010). It is possible that dietary modulation and nutritional supplementation serves only to bolster
normal health mechanisms that are a natural deterrent of chronic
health conditions such as AD without really possessing any discrete
disease speciﬁcity. Future investigations in the area of nutritional
and dietary prevention of AD will have to consider these potential
confounds and overcome them if nutritional and dietary supplementation and modiﬁcation are ever to become part of the clinical
care paradigm for the prevention and treatment of AD.
While the ﬁeld of interventional nutrition in AD is expanding at
an exciting pace and the latest developments in this ﬁeld are being
closely followed by researchers, clinicians, the public, and the lay
media, deﬁnitive clinical trials are lacking secondary to funding
limitations and opportunities, adherence to traditional empiric
clinical methodologies that seek to investigate single mechanisms
of disease pathogenesis and intervention, and the development
of strategies to overcome basic issues of control populations and
2 http://www.clinicaltrials.gov/ct2/results?term=curcumin+and+alzheimer
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incorporation of often complex interventional strategies for the
multi-faceted approaches that may be required to move the investigation of nutritional interventions for the prevention of AD
forward.
Given the complexity of the ﬁeld in regards to nutritional
interventions for the prevention of AD and the considerations
and limitations an available to date, it is important to draft
recommendations for advancing the ﬁeld in this regard. Recommendations stemming from this review include: (1) Expanding
research funding opportunities beyond those available from the
National Center for Complementary and Alternative Medicine
(NCCAM), to include funding from other NIH centers and
to encourage state-of-the-art and “gold-standard” research from
industry and private organizations; (2) Design of trial methodology and data analysis techniques to account for complexities
in dietary patterns that may inﬂuence investigations of single
nutriceutical agents or simple combinations of such agents, that
may be amenable to the desired goal of rigorous prospective scientiﬁc investigation of comprehensive dietary alterations in the
prevention of AD; (3) Incorporation of longer trial periods reﬂecting our increased understanding of the extensive (10–20 year)
prodromal period of AD where prevention may be most effective;
and (4) Broad scientiﬁc discovery from biological samples derived
from prospective clinical interventions focused on investigating
the basic mechanisms underlying the potential beneﬁcial effects
of nutritional interventional strategies including metabolomic,
antioxidant, immunologic, neuroprotective and cellular regenerative discoveries. The development of a fundamental framework
incorporating such features is necessary for advancing the ﬁeld
of nutritional interventional strategies for the prevention and
treatment of AD.
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